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Introduction {#sec001}
============

The exon-intron structure of genes is essential for cell type- and condition-specific gene expression regulation \[[@pone.0233978.ref001]\], maintaining genetic stability \[[@pone.0233978.ref002]\] and genome evolution \[[@pone.0233978.ref003]--[@pone.0233978.ref006]\] of higher eukaryotes.

Comprehensive genome annotation allows studying the basic statistical properties of introns. Particularly, introns are usually characterized by an ordinal number within the gene, the region length, and features of the nucleotide sequence. Another important numeric characteristic is the phase, i.e. the sum of the lengths of the preceding exons modulo 3, e.g. the phase 1 intron occurs after the first nucleotide of a codon.

It's known that there is an excess of phase 0 introns in all eukaryotic genomes \[[@pone.0233978.ref007]\]. The usual ratio of intron phases 0, 1, and 2 is nearly 5:3:2 \[[@pone.0233978.ref007]\]. The phase distribution of spliceosomal introns strongly correlates with the sequence conservation of splicing signals in the neighboring exons \[[@pone.0233978.ref008]\]. The relatively underrepresented phase 2 introns exhibit the lowest conservation rate, the relatively overrepresented phase 0 introns show the highest conservation level, and phase 1 introns have no special properties in regard to sequence conservation. In \[[@pone.0233978.ref009]\] it was shown that the creation of new exon-intron structures through genetic recombination, the exon shuffling, in metazoans is predominantly mediated by phase 1 introns (1--1 exon shuffling), whereas 0--0 exon shuffling prevails in non-metazoan organisms. 2--2 exon shuffling rate was insignificant in all organisms. Based on these data, the authors hypothesized that phase 0 introns are more ancient than phase 1 and 2 introns, but claimed that the genetic and selection mechanisms that lie behind the preference for shuffling 1--1 exons or domains remain largely unknown.

In \[[@pone.0233978.ref010]\] authors found a significant excess of phase 1 introns in the vicinity of the signal peptide cleavage site in human genes. It was suggested that the amino acid sequence of the signal peptide favors an enrichment of phase 1 AG\|G proto-splice sites in the vicinity of the cleavage site and the depletion of these sites in any phase within the peptide-encoding RNA sequence. However, in \[[@pone.0233978.ref011]\] authors claimed there were no disproportional excess of phase 1 AG\|G sites in the vicinity of the cleavage site and suggested an alternative scenario, where the excess of phase 1 introns was produced by 1--1 exon shuffling

A study of the *H*. *sapiens*, *D*. *melanogaster*, *C*. *elegans*, and *A*. *thaliana* genomes \[[@pone.0233978.ref012]\] showed increasing frequency of phase 0 introns and decreasing frequency of phase 1 when scanning genes from 5' to 3'. This tendency was specifically exhibited in the genomes of *Homo sapiens* and *Arabidopsis thaliana*, for which the emergence of new introns in the 3' region of genes was suggested to be the dominant process \[[@pone.0233978.ref012]\]. The authors also consider the high frequency of phase 1 introns immediately after the signal peptide to be a minor contributing factor for the observed gradient.

In \[[@pone.0233978.ref013]\] it was demonstrated that introns in tissue-specific and development-specific genes are longer than those in housekeeping genes. It was claimed that the share of the conserved sequence is higher in tissue-specific genes, which may indicate that the intron evolution is not neutral in general. It was also reported that the length of the conserved intronic DNA in a gene was correlated with the number of functional domains in the protein encoded by that gene. According to \[[@pone.0233978.ref014]\], the intronic burden of a gene (considering either the total length or the number of introns) is positively correlated with its evolutionary conservation which suggests functional importance of the genes with large intronic regions.

In \[[@pone.0233978.ref015]\] the authors claimed that the first introns are usually longer in eukaryotic genes, for first introns both inside 5\'-untranslated regions (5\' UTRs) or coding sequences (CDSs). A proposed explanation was that the increased length of first introns allowed presence of additional functional elements compared to 'normal' intron structure. Consistently, the fraction of conserved sequence in the first introns was found higher compared to that of all the downstream introns (see Fig 3A in \[[@pone.0233978.ref013]\]).

Despite the vast amount of information that is already known about introns, there is still a lack of work regarding the relationship between the intron length and the intron phase.

In our previous work \[[@pone.0233978.ref016]\] we considered 17 animal genomes of various taxons (including insects, fish, amphibians, reptiles, birds, and mammals) and demonstrated that shares of intron phases significantly varied with increasing lengths of considered introns, particularly, the share of phase 1 increased and reached phase 0 share at a certain threshold (\~100 kilobases (kb) in mammals).

In this work, we performed functional annotation of human and mouse orthologs satisfying particular intron phase and length constraints.

Materials and methods {#sec002}
=====================

We used GENCODE \[[@pone.0233978.ref017]\] gene annotations for *Homo sapiens* hg38 (GENCODE version 28) and *Mus musculus* mm10 (GENCODE version M18) genomes. The set of considered genes has been limited to protein-coding curated (HAVANA) transcripts with the transcript support level of 1. For each gene with several eligible transcripts, we selected the one with the maximum number of exons. Human-mouse orthologous pairs were extracted from the MGI database \[[@pone.0233978.ref018]\]. The resulting set consisted of 13823 orthologous gene pairs.

All introns were segregated into 4 groups by length: less than 5 kb (denoted \<5 below), between 5 kb and 10 kb (5--10), between 10 kb and 50 kb (10--50), and longer than 50 kb (\>50). Intron phases were marked ph0, ph1, and ph2 respectively for phase 0, phase 1, and phase 2. Every gene from orthologous pairs was annotated with the number of introns belonging to each of 12 possible \'phase-length\' groups, see [S1 Table](#pone.0233978.s004){ref-type="supplementary-material"}.

For GO enrichment analysis, the list of gene ontology (GO) terms associated with each gene was extracted from MGI \[[@pone.0233978.ref018]\]. Each pair of a \'phase-length\' group of introns and a GO-term was annotated with the number of orthologs associated with the GO-term and containing at least one intron of the given group (a) both in human and mouse, (b) in human only, (c) in mouse only, and (d) not containing such introns neither in human nor mouse, see [S2 Table](#pone.0233978.s005){ref-type="supplementary-material"}. With these data, we used Fisher\'s exact test \[[@pone.0233978.ref019]\] to estimate the statistical significance of the GO term enrichment for each \'phase-length\' group. P-values were corrected for multiple tested pairs using Benjamini-Hochberg (FDR) procedure \[[@pone.0233978.ref020]\]. GO terms with significant enrichment (passing 1% FDR) in both human and mouse were selected for further analysis, see [S3 Table](#pone.0233978.s006){ref-type="supplementary-material"}.

Results {#sec003}
=======

Phase 1 introns demonstrate a distinct pattern with multiple GO terms enriched in the group of length \> 50 kb unlike phases 0 and 2 that demonstrate strong enrichments of multiple GO terms only for shorter introns ([Fig 1](#pone.0233978.g001){ref-type="fig"}).

![Genes containing introns of particular length and phase are enriched with multiple GO-terms.\
Rows---\'phase-length\' intron groups, columns---GO-terms. The cells with significant enrichment (1% FDR) are colored. Color scale reflects the total number of genes associated with a particular GO term. Columns have been arranged manually by placing the GO-terms enriched with the shorter groups of introns on the left, GO-terms enriched with the groups of long introns on the right, and then sorting within those two halves of GO-terms by their sizes keeping similar rows close to each other. The GO-terms enriched with phase 1 introns longer than 50 kilobases only are emphasized with the black frame. Curly brackets mark out the clusters of similar GO-terms and are followed with the particular terms that demonstrate the most significant enrichments.](pone.0233978.g001){#pone.0233978.g001}

To perform an in-depth analysis, we created a subset of genes with ph1\_\>50 introns by gathering all such genes with at least one GO term enriched in ph1\_\>50 introns only (see [Table 1](#pone.0233978.t001){ref-type="table"} for the list of GO-terms). The resulting list consisted of 153 genes composed of 2235 exons, see [S4 Table](#pone.0233978.s007){ref-type="supplementary-material"}. Within CDSs, the genes included 742, 917, and 423 introns in phases 0, 1, and 2 respectively. Consistently, the selected genes showed a significant abundance of phase 1 introns longer than 50 kilobases ([S1 Fig](#pone.0233978.s001){ref-type="supplementary-material"}), while in the complete set of genes shares of phases 0 and 1 introns longer than 50 kilobases were comparable.

10.1371/journal.pone.0233978.t001

###### 25 GO-terms significantly associated with genes of the ph1\_\>50 introns group.

![](pone.0233978.t001){#pone.0233978.t001g}

  GO-term                                                                                  Number of associated genes with ph1\>50 introns   Total number of associated genes   Odds ratio   FDR
  ---------------------------------------------------------------------------------------- ------------------------------------------------- ---------------------------------- ------------ ----------
  GO:0007165 signal transduction                                                           63                                                739                                2.68         5.00E-06
  GO:0099056 integral component of presynaptic membrane                                    21                                                77                                 10.32        5.08E-09
  GO:0050804 modulation of chemical synaptic transmission                                  18                                                77                                 8.34         4.26E-06
  GO:0031225 anchored component of membrane                                                17                                                110                                4.97         8.9E-03
  GO:0099061 integral component of postsynaptic density membrane                           17                                                54                                 12.56        7.35E-08
  GO:0099055 integral component of postsynaptic membrane                                   16                                                67                                 8.55         3.07E-05
  GO:0043195 terminal bouton                                                               15                                                72                                 7.15         7.2E-04
  GO:0051965 positive regulation of synapse assembly                                       13                                                60                                 7.49         3.6E-03
  GO:2000300 regulation of synaptic vesicle exocytosis                                     13                                                54                                 8.59         9.4E-04
  GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules   12                                                38                                 12.50        1.1E-04
  GO:0007416 synapse assembly                                                              12                                                37                                 13.00        7.57E-05
  GO:0051966 regulation of synaptic transmission, glutamatergic                            11                                                25                                 21.25        7.36E-06
  GO:0032281 AMPA glutamate receptor complex                                               10                                                25                                 17.99        1.4E-04
  GO:0008066 glutamate receptor activity                                                   10                                                11                                 270.16       7.81E-10
  GO:0005246 calcium channel regulator activity                                            9                                                 28                                 12.75        7.4E-03
  GO:0035249 synaptic transmission, glutamatergic                                          9                                                 28                                 12.75        7.4E-03
  GO:0051968 positive regulation of synaptic transmission, glutamatergic                   9                                                 23                                 17.32        1.0E-03
  GO:0004970 ionotropic glutamate receptor activity                                        9                                                 15                                 40.43        8.35E-06
  GO:0046328 regulation of JNK cascade                                                     8                                                 20                                 17.92        4.7E-03
  GO:0036477 somatodendritic compartment                                                   8                                                 16                                 26.89        5.5E-04
  GO:2000311 regulation of AMPA receptor activity                                          7                                                 15                                 23.48        7.6E-03
  GO:0005003 ephrin receptor activity                                                      7                                                 14                                 26.84        4.2E-03
  GO:0005005 transmembrane-ephrin receptor activity                                        7                                                 14                                 26.84        4.2E-03
  GO:0015277 kainate selective glutamate receptor activity                                 5                                                 6                                  133.72       6.8E-03
  GO:0032983 kainate selective glutamate receptor complex                                  5                                                 6                                  133.72       6.8E-03

The first column lists GO-term accession numbers and their descriptions. The last column shows the FDR-corrected significance of the corresponding enrichment.

Assuming the Gene Ontology annotation is not comprehensive, we assembled the complete list of genes with ph1\_\>50-introns (507 genes) for further analysis, see [S4 Table](#pone.0233978.s007){ref-type="supplementary-material"}. Indeed, analysis of tissue-specific gene expression showed that both 507 and 153 groups are specifically expressed in brain tissues ([S2 Fig](#pone.0233978.s002){ref-type="supplementary-material"}).

We also performed an additional enrichment analysis of the 153 genes with respect to associated diseases having the entire set of 13823 genes as background. In agreement with brain-specific expression, we found associations with a number of mental disorders ([S3 Fig](#pone.0233978.s003){ref-type="supplementary-material"}), including schizophrenia and depression, which were detected as significant in three out of four annotation databases.

The excess of long phase 1 introns in the primary sublist of 153 genes can be caused by the presence of the signal peptide or with the 1--1 exon shuffling events.

Indeed, 83 out of 153 (54%) genes started with the signal peptide sequence (according to the UniprotKB \[[@pone.0233978.ref021]\], see [S4 Table](#pone.0233978.s007){ref-type="supplementary-material"}), which is significantly greater than the overall percentage of 17% in human genes (3596 out of 20365, according to the UniprotKB \[[@pone.0233978.ref021]\]). Furthermore, long phase 1 introns are preferably found at the 5\'-end of the spliced transcripts ([Fig 2](#pone.0233978.g002){ref-type="fig"}). Next, from 9 possible phase types of exons, only 1--1 exons are significantly enriched in the 153 genes (odds ratio of 2, FDR-corrected P-value \< 10^−30^, see [S4 Table](#pone.0233978.s007){ref-type="supplementary-material"}). Thus, the observed enrichment of long phase 1 introns is associated with both the presence of the signal peptide and with the 1--1 exon shuffling.

![Distribution of relative intron positions along the transcripts.\
(A) Introns shorter than 50 kilobases of the entire set of considered human genes. (B) Introns longer than 50 kilobases of the entire set of considered human genes. (C) Introns shorter than 50 kilobases of the group of 153 genes. (D) Introns longer than 50 kilobases of the group of 153 genes. Y axis: distribution density, X axis: the relative position of an intron within the spliced transcript. Phase 1 introns are shown in orange, phase 2 and 0 introns are shown together in gray.](pone.0233978.g002){#pone.0233978.g002}

Discussion {#sec004}
==========

As it\'s mentioned in Introduction, according to \[[@pone.0233978.ref011]\] the connection between phase 1 introns and the signal peptide may be explained by 1--1 exon shuffling events, and, according to \[[@pone.0233978.ref009]\], the preference for shuffling 1--1 exons remain largely unknown. We propose the following scenario to explain the observed associations.

First, the prevalence of phase 1 introns immediately after the signal peptide sequence \[[@pone.0233978.ref010]\] is caused by the conserved A, V, and G amino acids in the vicinity of the cleavage site \[[@pone.0233978.ref022]\]. This conservation is dictated by the (-3, -1) rule that states the residues at positions -3 and -1 (relative to the cleavage site) must be small and neutral for correct cleavage \[[@pone.0233978.ref022]\]. These three amino acids are coded by GNN codons which favor phase 1 introns since among the three positions of the AG\|G common exon-exon junction motif only the G\| position is strongly conserved and the other two are hardly specific \[[@pone.0233978.ref008]\]. The prevalence of phase 0 introns immediately after the ATG start codons (i.e. between codons 1 and 2 of the gene) observed in \[[@pone.0233978.ref023]\] can serve as the evidence that a single G\| position is enough to favor a specific intron phase. In turn, sharp depletion of introns in the middle of the signal peptide coding region \[[@pone.0233978.ref010]\] may be explained by the fact that the region can serve as a signal for an alternative nuclear export of an mRNA \[[@pone.0233978.ref024]\].

The excess of long phase 1 introns (and not short introns) is possibly caused by the generally longer first introns in eukaryotes \[[@pone.0233978.ref015]\]. The signal peptide sequence is always on the 5\'-end of the gene and consequently the intron immediately after it is often the first intron of the gene.

Next, we state the preference for shuffling 1--1 exons is caused exactly by the excess of phase 1 introns immediately after the signal peptide sequence (and not in the opposite direction of causality as earlier proposed in \[[@pone.0233978.ref011]\]).

First, there are several examples of the evolution governed by exon shuffling events in the genes composed of the signal peptide sequence followed by a phase 1 intron and another protein domain coding region, in particular, this was observed for serine proteases \[[@pone.0233978.ref025], [@pone.0233978.ref026]\], β-defensins \[[@pone.0233978.ref027]\], and scorpion venom genes \[[@pone.0233978.ref028]\].

Second, according to \[[@pone.0233978.ref029]\], the extracellular proteins in mammals evolve faster than the intracellular ones, and extracellular protein must start with the signal peptide. The observed faster evolution must have been governed by exon shuffling events since the modular proteins are mainly membrane and secreted proteins and the modular domains are mainly coded by 1--1 exons \[[@pone.0233978.ref003], [@pone.0233978.ref004], [@pone.0233978.ref030], [@pone.0233978.ref031]\]. The additional argument in favor of the above statement is that most of the recently duplicated genes encode membrane and secreted proteins \[[@pone.0233978.ref032]\].

We believe that such fast evolution caused by 1--1 exon shuffling close to the 5\'-end of the genes should have been made a significant contribution to the tendency of phase 1 to decrease and phase 0 to increase in the direction from 5\'- to 3\'-end of the gene observed in \[[@pone.0233978.ref012]\] (see [Fig 2](#pone.0233978.g002){ref-type="fig"}).

The selected group of 153 genes with a great excess of long phase 1 introns is consistently enriched with brain-specific genes, which are considered evolutionarily young and enriched with alternative splicing events \[[@pone.0233978.ref033]\], requiring high intronic burden.

Supporting information {#sec005}
======================

###### Phase distribution of long (longer than 50 kilobases) introns.

(PNG)

###### 

Click here for additional data file.

###### Tissue-specific gene enrichment.

\(a\) All 507 genes containing ph1\>50 introns. (b) 153 genes selected based on GO enrichment. Graphs have been generated with TissueEnrich \[[@pone.0233978.ref001]\]. (c) The top 50 genes (out of the 153 genes) with the largest total phase 1 introns size. The graph is generated with GTEx Multi Gene Query tool \[[@pone.0233978.ref002]\].

(PNG)

###### 

Click here for additional data file.

###### Disease and pathway enrichment analysis of the 153 genes.

Graphs have been generated with WebGestalt \[[@pone.0233978.ref003]\].

(PNG)

###### 

Click here for additional data file.

###### Number of introns of different phase and length in human-mouse orthologous gene pairs.

(XLSX)

###### 

Click here for additional data file.

###### Number of human-mouse orthologous gene pairs containing introns of different phase and length associated with particular GO-terms.

(XLSX)

###### 

Click here for additional data file.

###### GO-enrichment of specific phase-length intron groups.

(XLSX)

###### 

Click here for additional data file.

###### Lists of human gene names of 153 orthologous human-mouse gene pairs of interest and of 507 orthologous human-mouse gene pairs containing ph1\>50 introns both in human and mouse.

Particular spreadsheets present exon-intron structure of the 153 genes, the first phase 1 introns, and the unique functional protein domains coded by the 1--1 exons of the 153 genes. 1. Jain A, Tuteja G. TissueEnrich: Tissue-specific gene enrichment analysis. *Bioinformatics*. 2019 Jun 1;35(11):1966--7. doi: [10.1093/bioinformatics/bty890](https://doi.org/10.1093/bioinformatics/bty890) 2. Carithers LJ, Moore HM. The Genotype-Tissue Expression (GTEx) Project. *Biopreservation and Biobanking*. 2015 Oct 1;13(5):307. doi: [10.1089/bio.2015.29031.hmm](https://doi.org/10.1089/bio.2015.29031.hmm) 3. Wang J, Vasaikar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. *Nucleic acids research*. 2017 Jul 3;45(W1):W130-7. doi: [10.1093/nar/gkx356](https://doi.org/10.1093/nar/gkx356).

(XLSX)

###### 

Click here for additional data file.
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Additional Editor Comments (if provided):

Dear Dr. Baulin,

The paper was reviewered by 2 experts in the field. They have several suggestions, please, try to implement them. Some experiments may be hard to implement. For example, the alternative splicing is an interesting topic but the amount of isoforms is huge for some genes. I am not sure how to make a \"the background random model\", may be you will have an idea.

Best regards, Igor

===

Dear Prof. Rogozin,

We wholeheartedly thank you and the reviewers for careful evaluation of our manuscript and very valuable comments and suggestions. We did our best to revise the manuscript accordingly. Particularly, we extended Results, and fully rewrote Discussion. Please find our point-by-point response below.

On behalf of all authors,

Eugene Baulin

\-\-\--

Reviewer \#1: Review on the manuscript titled "Brain-related genes are specifically enriched with long phase 1 introns" by Baulin et al., 2020

The authors addressed the intron phase distribution dependence on length in 14000 human-mouse orthologous pairs. They provide phase distribution data in supplementary for mouse and human in 5 intron length bins: 0\<5kb\<10kb\<50kb\<\~

Next the authors checked each bin specific genes (intron-wise) for GO abundance, result provided in supplementary. They identified 153 genes (and how many introns?) in \>50kb bin were abundant in phase 1 (suppl fig1), and the genes were brain specific (suppl fig2). The authors noted specific codon distribution in the target sample.

===

We added the missing numbers (exons and introns) to the corresponding paragraph in the Results section.

\-\-\--

1\) The authors claim that the major biological impact of phase skew is codon frequency bias. While there could be some skewed codon preference, I personally doubt that it could be the major trait associated with the phenomena. There are some previous articles on the phase 1 bias in signal peptide -- containing genes (and it is the sample of more than 2000 genes), but no definite conclusions where made ever since the phenomenon's been reported. Also, this fact should be highlighted in the introduction and discussion.

===

We specifically thank the reviewer for this comment. We performed an additional analysis and realized the bias to be indeed related to the presence of the signal peptides. We have updated the Results and Discussion accordingly, and included the relevant references in the Introduction.

\-\-\--

2\) The authors made the major stress on GO ontology relation to the particular bins and phases: both tables S2 and S3 are devoted to that. It's my particular point that GO enrichment effect is rather speculative and cannot be (was not in the manuscript) the basis for any definite inference unless explicitly proved by some distinct biological hypothesis testing, or at least stating. Pooling the genes intron-wise look rather morbid for reader screening the data as well as overall sense exploring it (problem statement issue). There is \'viewable\' and \'accessible\' results in 153 'more than 50kb' bin onl , but it is the subject of more profound elaboration as I mentioned above

===

We have updated the Supplementary table 4 to include detailed information regarding the exon-intron structure of the selected genes as well as predicted Pfam domains coded by 1-1 exons, transmembrane domains and signal peptides.

\-\-\--

3\) There's no obvious biological ground/model of manifested relations provided in manuscript.

===

We did our best to re-check the related literature, and (including analysis related to comment 1) were able to formulate the hypothesis, explaining the observed phenomenon. We have updated the Discussion accordingly.

\-\-\--

4\) The authors provided multiple comparison scheme in the course of GO enrichment analysis Tables S2, S3), but no correction for multiple comparisons is observed (FDR)

===

The presented numbers were in fact FDR corrected for multiple tested pairs of a GO-term and a phase-length intron group. We changed the corresponding titles in the Supplementary table 3.

\-\-\--

5\) The figures and tables in the manuscript are quite lack of explicit description of the fields by the legends, while they are assumed to be self-sufficient (Table 2). Why there's a log score field, but no significance value? It would be good to mention the number of instances observed for each pattern in Table 2.

===

We have removed Table 2 in the revised version of the manuscript. We have added the missing caption to Table 1.

\-\-\--

Fig. 1 is quite awkward. The names are turned bottom to the top and overall non-transparent, it is advised to redesign it. Cannot see Fig 1 Title.

===

We have significantly redesigned Figure 1 to improve visual clarity.

\-\-\--

No description and column titles in Supplem. Table 3, last spreadsheet.

===

We have updated the Supplementary Table 3 which now includes a missing readme section with detailed description of the columns.

\-\-\--

6\) In the text: S1 Fig -\> Fig. 1; S6 Table-\> Table S6, etc.

===

In the original submission we followed the PLoS one guidelines regarding naming of supplementary figures and tables (\"S1 Fig\", \"S1 Table\" - as suggested in <https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf>). In case the used naming scheme is incorrect, we believe it can be resolved at the technical editing stage.

\-\-\--

7\) 153 genes are not specifically cortex genes, but rather brain-specific ones. Most of them express in various brain regions. So they may be called as brain-specific genes, but I\'m not insisting on that.

===

Fixed as suggested.

\-\-\--

8\) It is known that brain- specific genes are quite long and are enriched for alternative splicing rates. I haven't found any correspondent brain specific genes features description in the manuscript. I suggest to check the intron phases locations distribution in the set as well as to assess overall AS enrichment in these genes, their length and exons number distribution. I assessed median \# exons=15, median length=351kb, and 2.6 isoforms per gene on average in 153 genes sample, which is significantly larger than genome average. Given large exons number per gene, the phase 1 exons would have a distinct elevated RANDOM chance to occur within the large introns. In particular, I found that there is a definite (significant) overall skew of phase 1 introns in the 153-fold sample: 898: 911: 423 (0,1,2 phases). At least 46 genes within a sample contain signal peptide at the beginning, though it may not greatly impact the results. So, it may be relevant to assess the background random model for this particular sample.

===

Indeed, 71 genes out of 153 carry a (predicted) signal peptide at 5\' end. We were able to link this observation with phase 1 introns, and updated the Discussion accordingly. The reference to a review describing brain-specific features of the alternative splicing is included in the second-last paragraph of Discussion.

\-\-\--

Other than that, since 153 genes can affect at most 200 codons on the phase 1 splice junction sites which is rather small amount, and given the previous failed attempts to assign codon bias as a target trait for the phase skew phenomenon in signal peptide motif containing genes, I observe the lack of the basic mechanistic hypothesis for the phenomenon in the manuscript, though it does look intriguing at this stage.

===

This suggestion allowed us to significantly revise the manuscript. In the revised version, we argue that the codon bias in the vicinity of the cleavage site of the signal peptide is the reason for the intron phase skew. We explain the previous attempts to connect the phase skew with codon bias were unsuccessful due to the limited sequence conservation of the AG\|G exon-exon junction motif since its two flanking positions are very weak compared to the major G\| position.

\-\-\--

Reviewer \#2: The authors found that \"the observed increased share of phase 1 introns is linked with specific codon usage of brain-related genes, but further analysis is necessary to fully interpret of intron phase-length dependencies.\" I do not think that this is the best conclusion for a paper (it is the last sentence of the Abstract). \"Further analysis\" sounds kind of provocative. I wonder if the authors can provide something more informative as a conclusion in the Abstract.

===

We fully agree with this comment. We have revised the Abstract as well as a large part of the Introduction and the whole Discussion section.

\-\-\--

1\) The issue of codon usage of brain-related genes was discussed in details in Genome Biol Evol. 2018 Aug 1;10(8):1902-1919. doi: 10.1093/gbe/evy146.

Genome-Wide Changes in Protein Translation Efficiency Are Associated with Autism.

Rogozin IB1, Gertz EM1, Baranov PV2, Poliakov E3, Schaffer AA1.

The brain-specific codon usage is a controversial topic, it is better to desrcibe it more detail.

===

We were not able to provide stronger evidence supporting the significant involvement of the codon usage, and this part of our analysis was also criticized by the 1st reviewer. We have removed this subsection from the revised manuscript.

\-\-\--

2\) The observed phase tendencies may be a result of phase 1-1 domain shuffling, there is a discussion of this issue in

Domain mobility in proteins: functional and evolutionary implications.

Basu MK, Poliakov E, Rogozin IB.

Brief Bioinform. 2009 May;10(3):205-16.

===

Indeed, the observed prevalence of phase 1 introns was found to be connected with 1-1 exon shuffling coupled with the presence of the signal peptide.

\-\-\--

Minor revision:

The Table 1 looks really bad, the names in the first column are truncated. May be formatting issues.

===

FIXED.

\-\-\--
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PONE-D-20-04197R1

Dear Dr. Baulin,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Igor B. Rogozin

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The authors implemented suggestions, the paper is acceptable.

Reviewers\' comments:
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Brain-related genes are specifically enriched with long phase 1 introns

Dear Dr. Baulin:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Igor B. Rogozin

Academic Editor

PLOS ONE
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